| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolytic-Uremic Syndrome | D006463 | 2 associated lipids |
| Pancytopenia | D010198 | 6 associated lipids |
| Nervous System Diseases | D009422 | 37 associated lipids |
| Ataxia | D001259 | 20 associated lipids |
| Psoriasis | D011565 | 47 associated lipids |
| Urinary Tract Infections | D014552 | 11 associated lipids |
| Brain Edema | D001929 | 20 associated lipids |
| Pseudomonas Infections | D011552 | 25 associated lipids |
| Respiratory Insufficiency | D012131 | 10 associated lipids |
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Fukuda T et al. | Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. | 1991 | Int. Arch. Allergy Appl. Immunol. | pmid:1718889 |
| Murase N et al. | FK 506 prevents spontaneous diabetes in the BB rat. | 1991 | Transplant. Proc. | pmid:1703705 |
| Meiser BM et al. | Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. | 1991 | Lancet | pmid:1719321 |
| Watanabe K et al. | Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. | 1991 | Transplant. Proc. | pmid:1703706 |
| Moochhala SM et al. | Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721277 |
| de Paulis A et al. | Antiinflammatory effect of FK 506 on human basophils. | 1991 | Transplant. Proc. | pmid:1721309 |
| Reding R et al. | Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. | 1991 | Transplant. Proc. | pmid:1721341 |
| Hebert MF et al. | Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721373 |
| Eiras G et al. | Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. | 1991 | Transplant. Proc. | pmid:1703357 |
| Jacobs TW et al. | The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. | 1991 | Transplant. Proc. | pmid:1721403 |
| Abu-Elmagd KM et al. | Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721404 |
| Goebl MG | The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. | 1991 | Cell | pmid:1706222 |
| de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
| Kuroki H et al. | Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. | 1991 | Transplant. Proc. | pmid:1721436 |
| Miyahara H et al. | Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. | 1991 | Clin. Immunol. Immunopathol. | pmid:1712688 |
| Lhoëst G et al. | Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. | 1991 | Pharm Acta Helv | pmid:1722046 |
| Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
| Gailliot FP et al. | Fluidized bed adsorption for whole broth extraction. | 1990 Sep-Oct | Biotechnol. Prog. | pmid:1366874 |
| Naouri A and Tissot E | [Indications for liver transplantation in adults]. | 1990 Jun-Jul | J Chir (Paris) | pmid:1698800 |
| MacLeod AM and Thomson AW | [FK-506. A new immunosuppressive drug]. | 1990 Jul-Sep | Medicina (Firenze) | pmid:1706817 |
| Wasik M et al. | Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. | 1990 Jul-Aug | Immunopharmacology | pmid:1699911 |
| Dumont FJ et al. | Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. | 1990 | J. Immunol. | pmid:1688572 |
| Woo J et al. | Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. | 1990 | Clin. Exp. Immunol. | pmid:1689226 |
| Dumont FJ et al. | The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. | 1990 | J. Immunol. | pmid:1689353 |
| Brown Z and Neild GH | FK-506 and haemolytic uraemic syndrome. | 1990 | Lancet | pmid:1689442 |
| Thomas J et al. | The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. | 1990 | Transplantation | pmid:1689518 |
| Vathsala A et al. | Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. | 1990 | Transplantation | pmid:1689520 |
| Yamamoto K et al. | Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. | 1990 | Immunology | pmid:1689694 |
| Thomson AW | Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. | 1990 | Transplant. Proc. | pmid:1689883 |
| Zeevi A et al. | Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689884 |
| Morris RE et al. | Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. | 1990 | Transplant. Proc. | pmid:1689885 |
| Li PK et al. | The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. | 1990 | Adverse Drug React Acute Poisoning Rev | pmid:1703724 |
| Todo S et al. | Early trials with FK 506 as primary treatment in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689886 |
| McCauley J et al. | The effects of FK 506 on renal function after liver transplantation. | 1990 | Transplant. Proc. | pmid:1689887 |
| Kang Y et al. | Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. | 1990 | Transplant. Proc. | pmid:1689889 |
| Jain AB et al. | Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. | 1990 | Transplant. Proc. | pmid:1689900 |
| Fung JJ et al. | Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. | 1990 | Transplant. Proc. | pmid:1689901 |
| Zeevi A et al. | Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. | 1990 | Transplant. Proc. | pmid:1689902 |
| Imventarza O et al. | Renal transplantation in baboons under FK 506. | 1990 | Transplant. Proc. | pmid:1689903 |
| Monden M et al. | A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. | 1990 | Transplant. Proc. | pmid:1689904 |
| Ericzon BG et al. | Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey. | 1990 | Transplant. Proc. | pmid:1689905 |
| Murase N et al. | Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. | 1990 | Transplant. Proc. | pmid:1689906 |
| Hoffman AL et al. | The effect of FK 506 on small intestine allotransplantation in the rat. | 1990 | Transplant. Proc. | pmid:1689907 |
| Lee KK et al. | Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. | 1990 | Transplant. Proc. | pmid:1689908 |
| Ueda Y et al. | Induction of graft acceptance after dog kidney or liver transplantation. | 1990 | Transplant. Proc. | pmid:1689909 |
| Ohara K et al. | Toxicologic evaluation of FK 506. | 1990 | Transplant. Proc. | pmid:1689910 |
| Nalesnik MA et al. | The effect of FK 506 and CyA on the Lewis rat renal ischemia model. | 1990 | Transplant. Proc. | pmid:1689911 |
| Francavilla A et al. | FK 506 as a growth control factor. | 1990 | Transplant. Proc. | pmid:1689912 |
| Mazzaferro V et al. | Studies of the hepatotrophic qualities of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689913 |
| Kay JE et al. | The mechanism of action of FK 506. | 1990 | Transplant. Proc. | pmid:1689914 |
| Suzuki N et al. | Effects of a novel immunosuppressive agent, FK506, on human B cell activation. | 1990 | Clin. Exp. Immunol. | pmid:1690097 |
| McCauley J et al. | FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. | 1990 | Lancet | pmid:1690326 |
| Hoffman AL et al. | The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. | 1990 | Transplantation | pmid:1690469 |
| Woo J et al. | The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. | 1990 | Scand. J. Immunol. | pmid:1690915 |
| Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
| Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
| Morimoto T et al. | Pancreaticoduodenal allotransplantation with FK 506 in the dog. | 1990 | Transplant. Proc. | pmid:1691550 |
| Yasunami Y et al. | Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. | 1990 | Transplant. Proc. | pmid:1691557 |
| Maki N et al. | Complementary DNA encoding the human T-cell FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from cyclophilin. | 1990 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1695378 |
| Doe SE et al. | Early effects of the immunosuppressive drug FK-506 on signal transduction in lymphocytes. | 1990 | Biochem. Soc. Trans. | pmid:1695581 |
| Murase N et al. | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. | 1990 | Transplantation | pmid:1696405 |
| Propper DJ et al. | FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. | 1990 | Transplantation | pmid:1696409 |
| Maruyama M et al. | Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. | 1990 | Transplantation | pmid:1696410 |
| Standaert RF et al. | Molecular cloning and overexpression of the human FK506-binding protein FKBP. | 1990 | Nature | pmid:1696686 |
| Tropschug M et al. | Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. | 1990 | Nature | pmid:1696687 |
| Randall T | New antirejection drugs anticipated. | 1990 | JAMA | pmid:1696999 |
| Metcalfe S et al. | FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. | 1990 | Transplant. Proc. | pmid:1697107 |
| Morris RE et al. | A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. | 1990 | Transplant. Proc. | pmid:1697111 |
| Woo J et al. | Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. | 1990 | Transplant. Proc. | pmid:1697112 |
| Woo J et al. | Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. | 1990 | Transplant. Proc. | pmid:1697113 |
| Propper DJ et al. | Low-dose FK 506 inhibits sensitisation after blood transfusions. | 1990 | Transplant. Proc. | pmid:1697114 |
| Tiebosch A et al. | Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. | 1990 | Transplant. Proc. | pmid:1697115 |
| Dammeijer PF et al. | Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. | 1990 | Transplant. Proc. | pmid:1697116 |
| Imai K et al. | Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. | 1990 | Transplant. Proc. | pmid:1697117 |
| Iga C et al. | Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. | 1990 | Transplant. Proc. | pmid:1697118 |
| Deguchi K et al. | [Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]. | 1990 | No To Shinkei | pmid:1697182 |
| Murase N et al. | Prevention of spontaneous diabetes in BB rats with FK 506. | 1990 | Lancet | pmid:1697397 |
| Justice RM et al. | The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. | 1990 | Biochem. Biophys. Res. Commun. | pmid:1697463 |
| Todo S et al. | Liver, kidney, and thoracic organ transplantation under FK 506. | 1990 | Ann. Surg. | pmid:1697743 |
| Sakr MF et al. | FK 506 ameliorates the hepatic injury associated with ischemia. | 1990 | Life Sci. | pmid:1698241 |
| Isai H et al. | FK 506 and orthotopic liver transplantation in the rat. | 1990 | Transplant. Proc. | pmid:1699329 |
| Suzuki S et al. | In vivo 31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK506. | 1990 | Heart Vessels | pmid:1699922 |
| Bierer BE et al. | Probing immunosuppressant action with a nonnatural immunophilin ligand. | 1990 | Science | pmid:1700475 |
| Murase N et al. | FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. | 1990 | Transplantation | pmid:1700504 |
| Burke MD et al. | Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. | 1990 | Transplantation | pmid:1700507 |
| Wicker LS et al. | Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. | 1990 | Eur. J. Immunol. | pmid:1700753 |
| Sigal NH et al. | Observations on the mechanism of action of FK-506. A pharmacologic probe of lymphocyte signal transduction. | 1990 | Biochem. Pharmacol. | pmid:1700909 |
| Takai K et al. | Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. | 1990 | Clin. Exp. Immunol. | pmid:1702372 |
| Okubo Y et al. | FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. | 1990 | Clin. Exp. Immunol. | pmid:1702373 |
| Arita C et al. | Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. | 1990 | Clin. Exp. Immunol. | pmid:1702374 |
| Woo J et al. | Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion. | 1990 | Clin. Exp. Immunol. | pmid:1702375 |
| Mattila PS et al. | The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. | 1990 | EMBO J. | pmid:1702384 |
| Kawashima H et al. | Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. | 1990 | Invest. Ophthalmol. Vis. Sci. | pmid:1702408 |
| Wilkinson PC and Watson EA | FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. | 1990 | Immunology | pmid:1702750 |
| Metcalfe S and Milner J | Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. | 1990 | Immunol. Lett. | pmid:1702753 |
| Takada K et al. | Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. | 1990 | J. Chromatogr. | pmid:1703552 |
| Fung JJ et al. | Overview of FK506 in transplantation. | 1990 | Clin Transpl | pmid:1715740 |
| Pugh-Humphreys RG et al. | The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. | 1990 | Immunology | pmid:1696242 |
| Mochizuki M and Kawashima H | Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. | 1990 | Autoimmunity | pmid:1717007 |
| Ni M et al. | FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. | 1990 | Autoimmunity | pmid:1717008 |